Gary Ventolini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Gary Ventolini has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
R. Neiger
Perinatal Partners, Miami Valley Hospital Berry Building, Maternal Fetal Medicine, Dayton, OH, USA
4 shared publications- Ran Neiger
Department of Obstetrics and Gynecology, Wright State University, Dayton, Ohio, USA
3 shared publications Christopher S Croom
2 shared publicationsJiri D Sonek
2 shared publicationsR Neiger
Department of Obstetrics and Gynecology, Wright State University Boonshoft School of Medicine, Dayton, OH, USA
2 shared publicationsBeth Dektas
Department of Obstetrics and Gynecology, Boonshoft School of Medicine, Wright State University, Dayton, OH, USA
1 shared publication
Latest Publications
- 1 July 2012
- Published by Wolters Kluwer Health in Journal of Lower Genital Tract Disease
- Vol. 16 (3) , 271-274
Lichen Sclerosus
The purpose of our study was to compare clinical data regarding patients with pruritic lichen sclerosus (LS) at moderate or severe stages using 2 different therapies with a 5-year follow-up. The study was approved by the institutional review board and was presented as a retrospective clinical data review of patients with pruritic biopsy diagnosis LS who underwent therapy at our university private practice from 2002 to 2005. We compared the results of a weekly topical application of high-potency steroid (HPS) with a combined HPS and monthly anesthetic/steroid subdermal injection (ASI). Outcomes were timed to achieve pruritus-free status, the number of symptomatic recurrences, and patient satisfaction with therapy. Fifty-four patients were diagnosed with LS between 2002 and 2005. There were 13 patients who had mild-stage, 25 who had moderate-stage, and 16 who had severe-stage LS. Five-year follow-up data on 17 patients with moderate-stage LS and 14 patients with severe-stage LS were obtained. Time to pruritus free was 6 weeks with ASI and 19 weeks with HPS for moderate-stage LS (p = .04) and 9 weeks with ASI and 24 weeks with HPS for severe-stage LS (p = .03). Recurrences were more frequent on HPS for moderate-stage LS (p = .04) but not significant with HPS for severe-stage LS (p = .15). Only ASI was successful at treating patients with recalcitrant pruritus. In our population, patients with symptomatic moderate-stage LS seem to have a more rapid and prolonged response to ASI than to HPS but are less satisfied with the injections.
- 1 July 2012
- Published by Wolters Kluwer Health in Journal of Lower Genital Tract Disease
- Vol. 16 (3) , 271-274
Lichen Sclerosus
The purpose of our study was to compare clinical data regarding patients with pruritic lichen sclerosus (LS) at moderate or severe stages using 2 different therapies with a 5-year follow-up. The study was approved by the institutional review board and was presented as a retrospective clinical data review of patients with pruritic biopsy diagnosis LS who underwent therapy at our university private practice from 2002 to 2005. We compared the results of a weekly topical application of high-potency steroid (HPS) with a combined HPS and monthly anesthetic/steroid subdermal injection (ASI). Outcomes were timed to achieve pruritus-free status, the number of symptomatic recurrences, and patient satisfaction with therapy. Fifty-four patients were diagnosed with LS between 2002 and 2005. There were 13 patients who had mild-stage, 25 who had moderate-stage, and 16 who had severe-stage LS. Five-year follow-up data on 17 patients with moderate-stage LS and 14 patients with severe-stage LS were obtained. Time to pruritus free was 6 weeks with ASI and 19 weeks with HPS for moderate-stage LS (p = .04) and 9 weeks with ASI and 24 weeks with HPS for severe-stage LS (p = .03). Recurrences were more frequent on HPS for moderate-stage LS (p = .04) but not significant with HPS for severe-stage LS (p = .15). Only ASI was successful at treating patients with recalcitrant pruritus. In our population, patients with symptomatic moderate-stage LS seem to have a more rapid and prolonged response to ASI than to HPS but are less satisfied with the injections.
- 1 December 2011
- Published by SAGE Publications in Journal of Gynecologic Surgery
- Vol. 27 (4) , 241-243
Recurrent Colonization by Group B Streptococcus Causing Vulvovaginitis: Short Communications
Objective: The goal of this study was to assess oral penicillin response to Group B Streptococcus GBS in patients with symptomatic recurrent vulvovaginal colonization (SRVI) was designed. Methods: This study received approval from an internal review board. In patients with symptomatic recurrent vulvovaginal infections SRVI were screened for GBS, and GBS prevalence and penicillin response were assessed. A retrospective review of adults with SRVI was then performed in which GBS was cultured and all patients who had positive results received oral penicillin. Response was evaluated by symptoms and culture. Results: Of the 220 patients included, 22.3% were GBS-positive; 24.6% responded to one treatment, 20.1% required two treatments, 38.9% required three treatments; and 16.4% were unresponsive. GBS colonization was 22.3 %. Antibiotic response was 24.6% after one treatment and 55.3% of patients required three treatments; they were nonresponders and remained symptomatic. Conclusions: Screening for GBS in this population could be useful. (J GYNECOL SURG 27:241)
- 1 December 2011
- Published by SAGE Publications in Journal of Gynecologic Surgery
- Vol. 27 (4) , 241-243
Recurrent Colonization by Group B Streptococcus Causing Vulvovaginitis: Short Communications
Objective: The goal of this study was to assess oral penicillin response to Group B Streptococcus GBS in patients with symptomatic recurrent vulvovaginal colonization (SRVI) was designed. Methods: This study received approval from an internal review board. In patients with symptomatic recurrent vulvovaginal infections SRVI were screened for GBS, and GBS prevalence and penicillin response were assessed. A retrospective review of adults with SRVI was then performed in which GBS was cultured and all patients who had positive results received oral penicillin. Response was evaluated by symptoms and culture. Results: Of the 220 patients included, 22.3% were GBS-positive; 24.6% responded to one treatment, 20.1% required two treatments, 38.9% required three treatments; and 16.4% were unresponsive. GBS colonization was 22.3 %. Antibiotic response was 24.6% after one treatment and 55.3% of patients required three treatments; they were nonresponders and remained symptomatic. Conclusions: Screening for GBS in this population could be useful. (J GYNECOL SURG 27:241)
- 29 June 2011
- Vol. 63 (5) , 459-64
Conditions associated with placental dysfunction.
Placental dysfunction is a term to describe suboptimal placental function leading to variations in the fetal supply of all its necessary required nutrients as well as the disruption in the cleansing of fetal catabolic products. The dysfunctional placenta may interrupt the manufacturing of other essential factors involved in pregnancy conservation, can compromise the fetal appropriate, atraumatic and sterile medium to grow, the immunologic shield from maternal antibodies and the normal amniotic fluid levels. Placental dysfunction can lead to a group of disorders representing a diverse and important category of pathological processes conducting to fetal and neonatal morbidity and mortality. The mechanisms by which these inflammatory processes cause death and disability are diverse and can be separated into four distinct classes: first, placental damage with loss of function; second, induction of premature labor; third, release of inflammatory mediators; fourth, transplacental infection. Several conditions have been associated with placental dysfunction: IUGR, hypertension, hypoxic-ischemic injury, preterm labor, and fetal death.
- 29 June 2011
- Vol. 63 (5) , 459-64
Conditions associated with placental dysfunction.
Placental dysfunction is a term to describe suboptimal placental function leading to variations in the fetal supply of all its necessary required nutrients as well as the disruption in the cleansing of fetal catabolic products. The dysfunctional placenta may interrupt the manufacturing of other essential factors involved in pregnancy conservation, can compromise the fetal appropriate, atraumatic and sterile medium to grow, the immunologic shield from maternal antibodies and the normal amniotic fluid levels. Placental dysfunction can lead to a group of disorders representing a diverse and important category of pathological processes conducting to fetal and neonatal morbidity and mortality. The mechanisms by which these inflammatory processes cause death and disability are diverse and can be separated into four distinct classes: first, placental damage with loss of function; second, induction of premature labor; third, release of inflammatory mediators; fourth, transplacental infection. Several conditions have been associated with placental dysfunction: IUGR, hypertension, hypoxic-ischemic injury, preterm labor, and fetal death.
- 6 May 2011
- Vol. 56, 138-41
Clinical antibiotic response of mycoplasma and ureaplasma in patients with symptomatic recurrent vulvovaginal colonization.
To assess the prevalence of mycoplasmas in symptomatic patients diagnosed with recurrent vulvovaginitis and to assess the response to doxycycline and ciprofloxacin. We conducted a retrospective medical records review of patients who consulted our private referral center for vulvovaginal disease between January 2004 and December 2008. The study included all the patients with positive culture for mycoplasma, ureaplasma or both and who received oral antibiotic therapy. The initial antibiotic therapy was with doxycycline, and persistent positivity was treated with ciprofloxacin. The center's Institutional Review Board approved the study. The condition was assessed in 225 patients; 47 (24.4%) had a positive culture as follows: ureaplasma, 34 (72.3%), mycoplasma, 3 (6.4%) and both cultures positive was found in 10 (21.3%) of the patients. The initial clinical and bacteriologic response to doxycycline was observed in 25 (73.5%) patients, while 9 (26.5%) remained persistent positive (p = 0.03). Of the nonresponders 7 (77.8%) became bacteriologic negative with ciprofloxacin, and 2 (22.2%) remained positive (p = 0.23). The cost of each antibiotic was comparable: doxycycline at $12.33 per course and ciprofloxacin at $13.02 per course. The prevalence of mycoplasma was 1.3%, ureaplasma 15.1% and both cultures positive 4.4%. The most effective response in our patients was with doxycycline.
- 6 May 2011
- Vol. 56, 138-41
Clinical antibiotic response of mycoplasma and ureaplasma in patients with symptomatic recurrent vulvovaginal colonization.
To assess the prevalence of mycoplasmas in symptomatic patients diagnosed with recurrent vulvovaginitis and to assess the response to doxycycline and ciprofloxacin. We conducted a retrospective medical records review of patients who consulted our private referral center for vulvovaginal disease between January 2004 and December 2008. The study included all the patients with positive culture for mycoplasma, ureaplasma or both and who received oral antibiotic therapy. The initial antibiotic therapy was with doxycycline, and persistent positivity was treated with ciprofloxacin. The center's Institutional Review Board approved the study. The condition was assessed in 225 patients; 47 (24.4%) had a positive culture as follows: ureaplasma, 34 (72.3%), mycoplasma, 3 (6.4%) and both cultures positive was found in 10 (21.3%) of the patients. The initial clinical and bacteriologic response to doxycycline was observed in 25 (73.5%) patients, while 9 (26.5%) remained persistent positive (p = 0.03). Of the nonresponders 7 (77.8%) became bacteriologic negative with ciprofloxacin, and 2 (22.2%) remained positive (p = 0.23). The cost of each antibiotic was comparable: doxycycline at $12.33 per course and ciprofloxacin at $13.02 per course. The prevalence of mycoplasma was 1.3%, ureaplasma 15.1% and both cultures positive 4.4%. The most effective response in our patients was with doxycycline.
- 1 January 2011
- Published by SAGE Publications in Journal of Neonatal-Perinatal Medicine
- Vol. 4 (3) , 231-234
Intrauterine growth restriction after bariatric surgery
Objective: Studies have suggested that pregnancies in patients with gastric bypass surgery for obesity are uncomplicated if the procedure was performed 6 to 18 months before pregnancy. We aim to examine intrauterine growth restriction (IUGR) in patients who underwent gastric bypass for at least 18 months before conception and who had no other obstetric risk factors. Material and Methods: We reviewed pregnancy outcome of patients who underwent gastric bypass 18 to 48 months before pregnancy. Results: Total population was 44 patients: 35 had uncomplicated pregnancies and 9 (20.5%) had IUGR and oligohydramnios. Their pregnancies before bypass were uncomplicated. All 9 patients were labor induced at 34 to 35 weeks; seven of them delivered vaginally and two by cesarean. Birth weight ranged from 1728–2041 grams and hospital stay between 9–38 days. Conclusion: In our population, pregnancies in patients with gastric bypass were at increased risk of IUGR. The risk persists beyond 18 months post bypass surgery, therefore fetal growth should be monitored closely.
- 1 January 2011
- Published by SAGE Publications in Journal of Neonatal-Perinatal Medicine
- Vol. 4 (3) , 231-234
Intrauterine growth restriction after bariatric surgery
Objective: Studies have suggested that pregnancies in patients with gastric bypass surgery for obesity are uncomplicated if the procedure was performed 6 to 18 months before pregnancy. We aim to examine intrauterine growth restriction (IUGR) in patients who underwent gastric bypass for at least 18 months before conception and who had no other obstetric risk factors. Material and Methods: We reviewed pregnancy outcome of patients who underwent gastric bypass 18 to 48 months before pregnancy. Results: Total population was 44 patients: 35 had uncomplicated pregnancies and 9 (20.5%) had IUGR and oligohydramnios. Their pregnancies before bypass were uncomplicated. All 9 patients were labor induced at 34 to 35 weeks; seven of them delivered vaginally and two by cesarean. Birth weight ranged from 1728–2041 grams and hospital stay between 9–38 days. Conclusion: In our population, pregnancies in patients with gastric bypass were at increased risk of IUGR. The risk persists beyond 18 months post bypass surgery, therefore fetal growth should be monitored closely.
- Open Access
- 1 January 2011
- Published by Elmer Press, Inc. in Journal of Clinical Medicine Research
- Vol. 3 (2) , 59-64
Measuring Treatment Outcomes in Women With Vulvodynia
Vulvodynia or vulvar pain syndrome is a chronic, heterogeneous, and multifactorial gynecological condition with an estimated prevalence of 9 - 12%, broad and substantial effect on quality of life due to physical disabilities, psychological distress and sexual dysfunction. A rationale therapeutic approach for the treatment of vulvodynia is still under investigation. A review of treatment modalities proposed by most of the clinicians involved in managing these patients advocated initially utilizing non-invasive therapies and then to proceed gradually to more aggressive therapies. A multidisciplinary approach that includes behavioral science and neuroimaging is required and recommended. Additionally a team approach should be utilized to test and evaluate therapies including pelvic floor physiotheraphy, psychotherapy, microbiology and pharmacology. It is my hope that this review will assist in the understanding of vulvodynia and its measuring treatment outcomes and will provide a thrust in the right direction to once and for all clarify this complex multifactorial disorder affecting women. Treatment; Vulvodynia; Women.
- 1 January 2011
- Published by Elmer Press, Inc. in Journal of Clinical Medicine Research
- Vol. 3 (2) , 59-64
Open AccessMeasuring Treatment Outcomes in Women With Vulvodynia
Vulvodynia or vulvar pain syndrome is a chronic, heterogeneous, and multifactorial gynecological condition with an estimated prevalence of 9 - 12%, broad and substantial effect on quality of life due to physical disabilities, psychological distress and sexual dysfunction. A rationale therapeutic approach for the treatment of vulvodynia is still under investigation. A review of treatment modalities proposed by most of the clinicians involved in managing these patients advocated initially utilizing non-invasive therapies and then to proceed gradually to more aggressive therapies. A multidisciplinary approach that includes behavioral science and neuroimaging is required and recommended. Additionally a team approach should be utilized to test and evaluate therapies including pelvic floor physiotheraphy, psychotherapy, microbiology and pharmacology. It is my hope that this review will assist in the understanding of vulvodynia and its measuring treatment outcomes and will provide a thrust in the right direction to once and for all clarify this complex multifactorial disorder affecting women. Treatment; Vulvodynia; Women.
- 1 January 2010
- Published by SAGE Publications in Journal of Neonatal-Perinatal Medicine
- Vol. 3 (1) , 1-5
Management of pregnancies complicated by reduced fetal metabolic reserve
During labor, the obstetrician's role is to prevent maternal and fetal morbidity and mortality. High on the list of potential complications is intrapartum fetal acidemia leading to asphyxia. Factors that increase the risk of acidemia and poor fetal outcome include conditions that had affected the fetus prior to labor such as: intrauterine growth restriction, oligohydramnios and placental abruption. Recent advances in the antepartum assessment of fetal and placental reserve provide us with a better ability to predict the fetal tolerance of labor and delivery. Using this information helps to decrease the risk of intrapartum fetal injury and death.
- 1 January 2010
- Published by SAGE Publications in Journal of Neonatal-Perinatal Medicine
- Vol. 3 (1) , 1-5
Management of pregnancies complicated by reduced fetal metabolic reserve
During labor, the obstetrician's role is to prevent maternal and fetal morbidity and mortality. High on the list of potential complications is intrapartum fetal acidemia leading to asphyxia. Factors that increase the risk of acidemia and poor fetal outcome include conditions that had affected the fetus prior to labor such as: intrauterine growth restriction, oligohydramnios and placental abruption. Recent advances in the antepartum assessment of fetal and placental reserve provide us with a better ability to predict the fetal tolerance of labor and delivery. Using this information helps to decrease the risk of intrapartum fetal injury and death.
- Open Access
- 22 January 2009
- Published by Springer Nature in Journal of Perinatology
- Vol. 29 (4) , 276-279
Pregnancy outcome after placement of ‘rescue’ Shirodkar cerclage
Mid-trimester painless cervical dilation is associated with high rates of perinatal morbidity and mortality. ‘Rescue’ cerclage is one option in managing these patients. We evaluated pregnancy outcomes of women in whom we placed Shirodkar cerclage. We analyzed the pregnancy outcome of a retrospective cohort of women carrying singleton pregnancies who experienced late mid-trimester cervical dilation in whom we placed Shirodkar cerclage. Exclusion criteria were uterine contractions, bleeding, premature rupture of membranes and chorioamnionitis. Primary outcomes were gestational age at delivery, maternal, fetal and neonatal outcomes and surgical complications. Between January 2003 and December 2005, 68 patients met our inclusion criteria. The average maternal age was 26.4±8.3 years and the mean gestational age at the time of surgery was 19.6±3.2 weeks. Seven women opted for expectant management and 5 more were followed up by their referring physicians; the 12 of them were used as a comparison group. Fifty-six women underwent placement of Shirodkar cerclage. We were unable to place a cerclage in three women (5.1%) and all three delivered before 23 weeks. Of the 56 women who had cerclage, 14 (23.7%) delivered at term, 20 (33.9%) delivered between 34 and 36.9 weeks, 13 (22%) between 30 and 33.9 weeks, 6 (10.2%) between 24 and 29.9 weeks and 3 (5.1%) before 24 weeks. Median time from diagnosis to delivery was longer in the cerclage group (9.1 weeks) than in the comparison group (3.3 weeks P<0.01). When pregnancies are complicated by late mid-trimester cervical dilation, placement of Shirodkar cerclage in appropriately selected patients has the potential to be a beneficial therapeutic option.
- 22 January 2009
- Published by Springer Nature in Journal of Perinatology
- Vol. 29 (4) , 276-279
Open AccessPregnancy outcome after placement of ‘rescue’ Shirodkar cerclage
Mid-trimester painless cervical dilation is associated with high rates of perinatal morbidity and mortality. ‘Rescue’ cerclage is one option in managing these patients. We evaluated pregnancy outcomes of women in whom we placed Shirodkar cerclage. We analyzed the pregnancy outcome of a retrospective cohort of women carrying singleton pregnancies who experienced late mid-trimester cervical dilation in whom we placed Shirodkar cerclage. Exclusion criteria were uterine contractions, bleeding, premature rupture of membranes and chorioamnionitis. Primary outcomes were gestational age at delivery, maternal, fetal and neonatal outcomes and surgical complications. Between January 2003 and December 2005, 68 patients met our inclusion criteria. The average maternal age was 26.4±8.3 years and the mean gestational age at the time of surgery was 19.6±3.2 weeks. Seven women opted for expectant management and 5 more were followed up by their referring physicians; the 12 of them were used as a comparison group. Fifty-six women underwent placement of Shirodkar cerclage. We were unable to place a cerclage in three women (5.1%) and all three delivered before 23 weeks. Of the 56 women who had cerclage, 14 (23.7%) delivered at term, 20 (33.9%) delivered between 34 and 36.9 weeks, 13 (22%) between 30 and 33.9 weeks, 6 (10.2%) between 24 and 29.9 weeks and 3 (5.1%) before 24 weeks. Median time from diagnosis to delivery was longer in the cerclage group (9.1 weeks) than in the comparison group (3.3 weeks P<0.01). When pregnancies are complicated by late mid-trimester cervical dilation, placement of Shirodkar cerclage in appropriately selected patients has the potential to be a beneficial therapeutic option.
- 1 January 2009
- Published by Taylor & Francis in Journal of Obstetrics and Gynaecology
- Vol. 29 (7) , 648-650
Vulvodynia, a step-wise therapeutic prospective cohort study
Vulvodynia is characterised by the presence of vulval allodynia (pain evoked by non-painful stimuli) and vulval dysaesthesias (burning, soreness, rawness, stinging and irritation). We assessed a protocol for the evaluation and management of vulvodynia. The protocol was based on the most recent evidence available. We began a simple evaluation and proceeded to an aggressive one. From the cohort of 74 patients, 69 patients (93.2%) were adherent to the protocol. A total of 25 patients (36.3%) improved after antibiotic therapy: 14 patients (20.4%) had a positive fungal culture and 11 patients (15.9%) had a positive bacterial culture; none with a positive viral culture. Eight patients (11.6%) improved with dietary modification. Ten patients (14.5%) benefitted from tricyclic medications; 13 patients (18.8%) improved after gabapentin therapy; 13 patients (18.8%) did not show improvement of their condition. Some 56 patients (81.2%) manifested an improvement of their symptoms, which allowed them to achieve painless sexual intercourse.
- 1 January 2009
- Published by Taylor & Francis in Journal of Obstetrics and Gynaecology
- Vol. 29 (7) , 648-650
Vulvodynia, a step-wise therapeutic prospective cohort study
Vulvodynia is characterised by the presence of vulval allodynia (pain evoked by non-painful stimuli) and vulval dysaesthesias (burning, soreness, rawness, stinging and irritation). We assessed a protocol for the evaluation and management of vulvodynia. The protocol was based on the most recent evidence available. We began a simple evaluation and proceeded to an aggressive one. From the cohort of 74 patients, 69 patients (93.2%) were adherent to the protocol. A total of 25 patients (36.3%) improved after antibiotic therapy: 14 patients (20.4%) had a positive fungal culture and 11 patients (15.9%) had a positive bacterial culture; none with a positive viral culture. Eight patients (11.6%) improved with dietary modification. Ten patients (14.5%) benefitted from tricyclic medications; 13 patients (18.8%) improved after gabapentin therapy; 13 patients (18.8%) did not show improvement of their condition. Some 56 patients (81.2%) manifested an improvement of their symptoms, which allowed them to achieve painless sexual intercourse.
- 1 September 2008
- Vol. 53 (9) , 667-71
The impact of maternal body mass on the effectiveness of 17 alpha-hydroxyprogesterone caproate.
To examine the impact of maternal prepregnancy body mass index (BMI) on rates of recurrent preterm delivery (PTD) in women receiving 17alpha-hydroxyprogesterone caproate (17P) prophylaxis. The study population was identified from a large perinatal database containing prospectively collected information from women at high risk for PTD. We included patients with a current singleton pregnancy and a history of PTD who received weekly nursing visits and 17P 250 mg intramuscular injections beginning at 16.0 to 20.9 weeks' gestation. The data were stratified by number of prior PTDs (1 or >1) and maternal prepregnancy BMI (lean, normal, overweight and obese). Primary study outcomes included the rates of recurrent PTD at <35 and 32 weeks' gestation, and pregnancy loss at <24 weeks' gestation. Delivery outcomes for 606 women receiving 17P were analyzed. There were no significant differences found in the incidence of preterm labor, the rates of recurrent PTD or pregnancy loss at <35, 32 or 24 weeks between the BMI groups. Maternal prepregnancy BMI does not appear to influence the rates of recurrent PTD in women with singleton gestation receiving 17P prophylaxis. Larger studies are needed to confirm our findings.
- 1 September 2008
- Vol. 53 (9) , 667-71
The impact of maternal body mass on the effectiveness of 17 alpha-hydroxyprogesterone caproate.
To examine the impact of maternal prepregnancy body mass index (BMI) on rates of recurrent preterm delivery (PTD) in women receiving 17alpha-hydroxyprogesterone caproate (17P) prophylaxis. The study population was identified from a large perinatal database containing prospectively collected information from women at high risk for PTD. We included patients with a current singleton pregnancy and a history of PTD who received weekly nursing visits and 17P 250 mg intramuscular injections beginning at 16.0 to 20.9 weeks' gestation. The data were stratified by number of prior PTDs (1 or >1) and maternal prepregnancy BMI (lean, normal, overweight and obese). Primary study outcomes included the rates of recurrent PTD at <35 and 32 weeks' gestation, and pregnancy loss at <24 weeks' gestation. Delivery outcomes for 606 women receiving 17P were analyzed. There were no significant differences found in the incidence of preterm labor, the rates of recurrent PTD or pregnancy loss at <35, 32 or 24 weeks between the BMI groups. Maternal prepregnancy BMI does not appear to influence the rates of recurrent PTD in women with singleton gestation receiving 17P prophylaxis. Larger studies are needed to confirm our findings.